TOP TEN perturbations for 39107_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39107_at
Selected probe(set): 202245_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39107_at (202245_at) across 6674 perturbations tested by GENEVESTIGATOR:

VTX-2337 study 1 / untreated monocyte sample

Relative Expression (log2-ratio):3.3022652
Number of Samples:3 / 3
Experimental VTX-2337 study 1
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities.
Control untreated monocyte sample
Peripheral blood monocytes isolated from healthy donors.

VTX-2337 study 1 / 3M-055 study 1

Relative Expression (log2-ratio):2.4578094
Number of Samples:3 / 3
Experimental VTX-2337 study 1
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities.
Control 3M-055 study 1
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM 3M-055 drug, which represents a TLR7 (Toll-like receptor 7) agonist.

prostate cancer study 8 (ptasc) / prostate cancer study 8 (psfmc)

Relative Expression (log2-ratio):2.3781052
Number of Samples:2 / 5
Experimental prostate cancer study 8 (ptasc)
CD90+ FACS sorted prostate tumor-associated stromal cell (ptasc) samples from patients with primary prostate cancer collected after radical prostatectomy.
Control prostate cancer study 8 (psfmc)
CD49a+ FACS sorted prostate stromal fibromuscular cell (psfmc) samples from patients with primary prostate cancer collected after radical prostatectomy.

engineered skin substitute study 2 (intermediate) / engineered skin substitute study 1 (intermediate)

Relative Expression (log2-ratio):-2.2252913
Number of Samples:6 / 3
Experimental engineered skin substitute study 2 (intermediate)
Human skin substitutes tissue samples collected after 14 and 28 days after transplantation to athymic mice.
Control engineered skin substitute study 1 (intermediate)
Human skin substitutes tissue samples collected after 7 days in culture.

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):-2.2132702
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (10000 uM; Hep-G2) / vehicle (PBS) treated Hep-G2 cell sample

Relative Expression (log2-ratio):-2.152813
Number of Samples:3 / 6
Experimental 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (10000 uM; Hep-G2)
Hep-G2 cells exposed to 10000 uM 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (dissolved in PBS) for 72 hours. Cells were exposed to the chemical when 80% confluence was reached. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:---
Control vehicle (PBS) treated Hep-G2 cell sample
Hep-G2 cells treated with vehicle (PBS) for 72 hours. Cells were exposed to the vehicle when 80% confluence was reached.

keratinocyte differentiation study 2 (KLF4 siRNA) / keratinocyte differentiation study 2

Relative Expression (log2-ratio):2.1355352
Number of Samples:2 / 2
Experimental keratinocyte differentiation study 2 (KLF4 siRNA)
KLF4 (Kruppel-like factor 4) depleted primary neonatal keratinocytes differentiated with 1.2 mM calcium for 3 days. Keratinocytes obtained from freshly isolated foreskin were grown in keratinocyte-SFM medium supplemented with epidermal growth factor and bovine pituitary extract. KLF4 depletion was done using siRNAs: KLF4i(A): CCGAGGAGTTCAACGATCT; KLF4i(B): TGACCAGGCACTACCGTAA. Differentiation was induced at 100% confluency.
Control keratinocyte differentiation study 2
Primary neonatal keratinocytes differentiated with 1.2 mM calcium for 3 days. Keratinocytes obtained from freshly isolated foreskin were grown in keratinocyte-SFM medium supplemented with epidermal growth factor and bovine pituitary extract. Differentiation was induced at 100% confluency.

conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):2.1122723
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS27a)
CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

OPM-1 / MM1.S

Relative Expression (log2-ratio):-2.1105413
Number of Samples:4 / 4
Experimental OPM-1
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-resistant. Synonyms:OPM1 Cellosaurus code:
Control MM1.S
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-sensitive. Parental cell line:: MM.1 Synonyms:MM.1S; MM1-S; MM-1S; MM1S Cellosaurus code:

ketoconazole study 6 (15uM) / vehicle (DMSO) treated hepatocyte sample

Relative Expression (log2-ratio):2.1089344
Number of Samples:2 / 2
Experimental ketoconazole study 6 (15uM)
Hepatocytes treated with compound: ketoconazole (15uM; CHEMBL75) for 24 hours. ATC code:, ,
Control vehicle (DMSO) treated hepatocyte sample
Hepatocytes treated with vehicle (DMSO) for 24 hours.